CAMBRIDGE, Mass., Feb. 3, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of 4,192,679 shares of its common stock. The offering is expected to consist of 3,000,000 shares to be offered by Epizyme and 1,192,679 shares to be offered by existing stockholders. Epizyme will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Epizyme intends to grant the underwriters a 30-day option to purchase up to 628,901 shares of common stock.
Epizyme intends to use proceeds from the offering, together with its existing cash and cash equivalents, as follows:
- To fund the company's share of the global development costs of clinical development of EPZ-5676, including the costs of the expansion stage of its ongoing Phase 1 clinical trial of EPZ-5676 in MLL-r adult patients and MLL-PTD adult patients and its planned Phase 1b clinical trial of EPZ-5676 in MLL-r pediatric patients;
- If the company exercises its opt-in right to co-develop, co-commercialize and share profits in the United States for EPZ-6438, to fund a portion of its share of U.S. development costs for EPZ-6438, including the costs of its planned Phase 2 clinical trial of EPZ-6438 in non-Hodgkin lymphoma patients with EZH2 point mutations as part of its ongoing Phase 1/2 clinical trial of EPZ-6438 and its planned Phase 2 clinical trial of EPZ-6438 in synovial sarcoma patients;
- To fund research and development to build the company's product platform and advance its pipeline of preclinical product candidates; and
- For working capital and general corporate purposes.
Citigroup, Cowen and Company, LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. JMP Securities LLC, Wedbush Securities Inc. and BTIG LLC are acting as co-managers for the offering. The offering is being made only by means of a prospectus, copies of which, when available, may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at firstname.lastname@example.org, or by phone at 800-831-9146; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, phone (631) 274-2806, fax (631) 254-7140; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at Syndicate@Leerink.com, or by phone at 1-800-808-7525.
Although a registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, it has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc., including statements about the company's anticipated public offering, anticipated use of proceeds, future operations, clinical development of the company's therapeutic candidates, expectations regarding future clinical trials or expansion of ongoing clinical trials, expectations regarding the company's cash balance and future expectations and plans and prospects for the company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials and other factors discussed in the "Risk Factors" section of the company's 10-Q filed with the Securities and Exchange Commission on October 23, 2013. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date hereof.
SOURCE Epizyme, Inc.